A combination therapy of entecavir and short-term administration of IFN-β have a potent effect in rapidly suppressing HBV replication in the early phase of hepatitis and may be effective and safe for the treatment of HBV reactivation-related hepatitis. This evidence concerns the gene IFNB1 and hepatitis A virus infection.